Analyst firms · Leerink Partners · AVIR
Leerink Partners AVIR price target and rating history
Atea Pharmaceuticals Inc. (AVIR) · Health Care
Leerink Partners rates Atea Pharmaceuticals Inc. (AVIR) Market Perform with a $9 price target, as of its latest action on Mar 1, 2022. It has published 6 rating actions on AVIR since September 2021, including 0 upgrades and 2 downgrades.
- Current rating
- Market Perform
- Price target
- $9
- Median target, all firms
- Too few
- Actions on AVIR
- 6
Leerink Partners price target on AVIR
Every Leerink Partners rating on AVIR
- Mar 1, 2022
- Feb 16, 2022
- Nov 18, 2021
- Nov 18, 2021
- Oct 20, 2021
- Sep 9, 2021
Questions about Leerink Partners and AVIR
- What is Leerink Partners's price target for AVIR?
- Leerink Partners's latest stated price target for Atea Pharmaceuticals Inc. (AVIR) is $9, from its action on Mar 1, 2022.
- What is Leerink Partners's rating on AVIR?
- Leerink Partners rates AVIR Market Perform, a neutral rating, as of Mar 1, 2022.
- When did Leerink Partners last change its view on AVIR?
- On Mar 1, 2022, Leerink Partners cuts its price target to $9 from $10, keeps Market Perform.
More AVIR rating histories
All Leerink Partners ratingsAVIR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.